Cannabis is a major growth market in North America, but not all areas of cannabis will see the same growth. THC, the psychoactive cannabis property, still remains under scrutiny by some U.S. lawmakers, but it appears the tide has turned and recreational cannabis use will continue to be legalized across the United States. Canada also appears to be nearing its goal to legalize marijuana for recreational use, as promised by Prime Minister Trudeau but this will take some time and face hurdles along the way.

One of the major growth areas of the cannabis market is Cannabidiol (CBD). CBDs are the non-psychoactive part of the cannabis plant. In other words, CBDs do not get you high. Instead, CBDs are seen as a medical and health application that can treat a wide range of illnesses and ailments.

CBD growth is forecast to continue to skyrock through 2020. According to The Hemp Business Journal, the CBD market will be worth $2.1 billion in 2020, an increase of 700%, over 2016. Some experts say that forecast is not bullish enough. According to Greenwave Advisors’ Matt Karnes, the CBD market could be worth $3 billion by 2021, citing greater legality and application to use CBDs across the United States.

Source: MoneyMorning.com

It appears there may be some logic behind Mr. Karnes’s beefed up outlook on the CBD markets. There are 22 U.S. States that allow cannabis in one form or another. If predictions are correct, then an additional six states are positioned to similarly legalize marijuana in 2017. This is great for THC and CBD producers, but with major scrutiny still on THC, CBD will continue to capitalize and become the go-to for medical marijuana.

As more companies utilize CBDs in their pharmaceuticals and treatments, the Cannabidiol market is set to be a major benefactor. After all, it is the CBDs that provide the vast majority of the medicinal qualities in cannabis.

Corix Biosciences (OTCQB: CXBS) Recent Developments:

Click on the dates to get the full story.

November 7, 2017 – Corix Bioscience Inc. (OTCQB: CXBS) has purchased 100% of Pharmaceutical Development Corp., allowing Corix to commence selling its proprietary cannabis products internationally.

Michael Ogburn, Corix Bioscience CEO, stated, “This is a defining moment for our company. It allows us to grow and manufacture cannabis in Lesotho and distribute our products to dozens of other countries. It will allow us to accelerate our growth very quickly. This deal will help us grow into the powerhouse company we anticipate to be in 2018.”

November 2, 2017 – CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Corix Biosciences Inc. (OTCQX: CXBS) and its focus on standardized tissue culture propagation of cannabidiol, hemp, and cannabis genetics.

The Hemp Business Journal estimates that hemp industry sales reached $688 million in 2016, representing a 22% compound annual growth rate. By 2020, the same researchers believe that the hemp industry will expand to more than $1.8 billion, driven primarily by the rise of hemp-based cannabidiol (CBD) products. These products could make a dent in the $17.7 billion opioid market, especially given emerging research and renewed political pressure.

October 5, 2017 – Corix Bioscience Inc. (OTCQB: CXBS) has entered into a contract to purchase a 46,060 square foot building in Carson City, Nevada. Closing is expected to occur on or before November 4, 2017. Purchase price for the building was finalized at $1,300,000.

The building will serve as Corix Bioscience’s new research and development laboratory with an indoor grow facility specifically for their industrial hemp genetics. Genetics of industrial hemp and cannabis is the core of Corix’s business.

September 7, 2017 – Corix Bioscience Inc. (OTCQB: CXBS) formally announces that it is acquiring 3 California cannabis licenses from California-based brand, E&B Investments LLC, for $2,000,000, consisting of $250,000 cash and the balance in restricted common stock. A deposit was given on August 29, 2017 with the closing date scheduled for September 8, 2017.

The licenses consist of: (1) Type 3A (large indoor cultivation), (1) Type 6/7 (manufacturing products using volatile and non-volatile solvents), and (1) Type 11 (distribution). All licenses are addressed to an existing 20,000 square foot cultivation facility and 1,500 square foot office in Adelanto, California. Corix will assume the 8-year lease and is in discussions to acquire the building and land. Further build-out on the building is anticipated to start immediately and Corix anticipates growing to begin by the end of September of 2017.

August 16, 2017 – Corix Bioscience Inc. (OTCQB: CXBS) announced a major sales agreement with Positively Green Organics, LLC. (PGO) to sell up to 22,000 pounds of hemp from 150 acres of PGO’s harvest monthly.

Under the agreement, PGO will deliver their industrial hemp flower or “bud,” to one of Corix’s facilities, where Corix will package it for storage and then sell the product on the open pharmaceutical market where it can bring approximately $575 per pound. The sales of the hemp will yield Corix 34% of the gross proceeds.

August 11, 2017 Corix Bioscience Inc. (OTCQB: CXBS), a next generation tissue cell culture to pharmaceutical grade cannabinoid oil (CBD) manufacturer, announces that they will move their tissue cell culture and research divisions into a new 10,122 square foot laboratory in Carson City, Nevada on a three-year lease. The lease commenced on August 1st.

This move will enable Corix to produce over 3 million plantlets in the immediate future and set them up to double that in the second full year. This new laboratory will be the first known tissue culture facility focused exclusively on the hemp and cannabis market. Until now, Corix relied on outside suppliers for seeds and clones. This will bring all propagation in-house. Part of the laboratory will be dedicated to the research of their proprietary CBD products and will require adding about 8 new employees.

One company well positioned to be among the top contenders in the organic and pharmaceutical-grade CBD market is Corix Bioscience, Inc. (OTCQB: AHIT).

Overview: Corix Bioscience, Inc. (OTCQB: AHIT)

Corix Bioscience, Inc. (OTCQB: AHIT) is in the developing stages of becoming potentially the largest producer of certified organic CBD oil within the United States. The company plans to use a fully integrated business model that covers seed-to-shelf, which includes planting, cultivation, harvesting, processing, and commercialization.

Corix Bioscience, Inc. (OTCQB: AHIT) currently has lease agreements on 200 acres of industrial hemp cultivation fields and plans to have around 400 acres leased  by the end of 2017. The company also maintains a series of greenhouses to help expand cloning and proprietary strain development. Greenhouses are able to grow year-round, if environmental controls are in place.

Source: CorixBioscience.com

Corix Bioscience, Inc. (OTCQB: AHIT) is currently undergoing a complete transformation from its old entity, American Housing Income Trust, Inc. In a Schedule 14C filing in May 2017, Corix Bioscience, Inc. (OTCQB: AHIT) announced a name change and conversion from a Maryland to a Wyoming corporation.

Tissue Culture and Deep Genetics to Develop New Strains

Being that a vast majority of the company’s cultivation fields are outdoor, there will be an offseason just there is for all other outdoor cannabis growers. However, that won’t stop Corix Bioscience, Inc. (OTCQB: AHIT)…

The company plans to develop unique, proprietary, and patent-able cannabis strains using tissue culture and deep genetics.

What is tissue culture?

Tissue culture occurs when you grow tissues and cells separate from the organism. As it is growing separately, the cells are exposed to variety of controlled factors that allow researchers to grow a unique and proprietary plant very quickly. According to AgriForest Bio-Technologies, Ltd., there are three main steps in the tissue culture process:

Tissue Culture Facility Construction Plans

On June 5, 2017, Corix Bioscience, Inc. (OTCQB: AHIT) announced it has signed a contract with Segra International, Inc. to build a state-of-the-art tissue culture facility in Nevada. The new facility will allow the company to begin making adjustments to cannabis seed cells and ultimately, its DNA. The goal is to create strains with greater production, stability, and higher yield. These newly developed strains is what will be patented.

Source: Theganjier.com

In addition to the 44,000 square foot tissue culture facility, the company is working on an attached 180,000 square foot greenhouse. Management says this would be enough to produce over 1 million industrial hemp seedlings, which will then be moved to the standard greenhouse in order to “harden” for a month. Then the plant is moved to the cultivation fields for full growing. 

AHIT: Financial and Industry Analysis

Corix Bioscience, Inc. (OTCQB: AHIT) maintains a market cap of $8.91 million, as of June 2017. The organic CBD oil producer has a share structure consisting of 500 million authorized shares, 19.79 million outstanding shares, and a float consisting of 850,000 shares, as of June 2017.

As Corix Bioscience, Inc. (OTCQB: AHIT) continues to go through a reorganization, management estimates that as the company’s industrial hemp operations ramp up later this year and into early next year, the company expects to sees its first major revenue-producing year in 2018.

Here are five other companies that have similar operations to Corix Bioscience, Inc. (OTCQB: AHIT) and could be used to help find a fair valuation for the company:

PotNetwork Holdings, Inc. (OTC Pink: POTN) is a diversified holdings company, which has stake in the premium CBD market through its subsidiary, Diamond CBD. Diamond CBD has been a strong revenue generator for the company and is the most valuable subsidiary under its control. PotNetwork Holdings, Inc. has a market cap value of $5.84 million, as of June 2017. Furthermore, the company maintains a share structure consisting of 500 million authorized shares, 94.33 million outstanding shares, and a float consisting of 16.87 million shares, as of June 2016. During the first quarter, the company reported revenues of $1.86 million and net income of $153,000.

Source: corixbioscience.com

AXIM Biotechnologies, Inc. (OTCQB: AXIM) is engaged within the research, discovery, development, and commercialization of CBD-based pharmaceutical products. As of June 2017, AXIM Biotechnologies, Inc. has a market cap of $541.47 million. Furthermore, the company maintains a share structure consisting of 300 million authorized shares, 52.57 million outstanding shares, and a float consisting of 35.21 million shares, as of May 2017. During the first quarter, AXIM Biotechnologies, Inc. reported total revenue of $18,000 and a net loss of ($524,000).

United Cannabis Corp. (OTCQB: CNAB) is a diversified cannabis company, which provides everything from consulting services and technology solutions to CBD oil development and product production. The company is currently undergoing clinical trials on its Parana CBD compounds. As of June 2017, United Cannabis Corp. has a market cap of $52.87 million. Furthermore, the company has a share structure consisting of 100 million shares authorized, 51.33 million shares outstanding, and a float consisting of 15.2 million shares, as of May 2017. During the first quarter, United Cannabis Corp. reported total revenues of $189,000, and a net loss of ($815,000).

Hemp, Inc. (OTC Pink: HEMP) operates as an industrial hemp company, and constructs a wide range of every-day type products from hemp. The industrial hemp company has a market cap consisting of $17.8 million, as of June 2017. Furthermore, the company maintains a share structure consisting of 5.5 billion shares authorized, and 754.03 million shares outstanding, as of June 2016. During the first quarter, Hemp, Inc. reported total revenues of $27,456 and a net loss of ($15.86 million).

GW Pharmaceuticals PLC (NASDAQ: GWPH) is a U.K.-based company that develops and commercializes CBD-based pharmaceuticals. The company’s flagship product, Sativex, is a spray to help treat spasticity from multiple sclerosis. In addition, the company has various other CBD-based treatments currently undergoing clinical trials. As of June 2017, GW Pharmaceuticals PLC maintains a market cap of $2.47 billion, 25.33 million shares outstanding, and a float consisting of 21.83 million shares. During the first quarter 2017, the company reported total revenue of GBP 1.63 million and a net loss of (GBP 34.37 million).

Just by looking at the basics, it appears Corix Bioscience, Inc. (OTCQB: AHIT) is undervalued relative to some of its peers. AXIM Biotechnologies, Inc. is by far the most overvalued stock, as the company reported total revenue of only $18,000, yet it has a market cap value of $541.47 million. However, it does show that Corix Bioscience, Inc. (OTCQB: AHIT) has a bright future, as investors and patients are flocking to CBDs at a record pace. Experts continue to argue over exactly how much the CBD market will be worth, but all agree that the 700%+ growth market is one that cannot be ignored.

Corix Bioscience, Inc. (OTCQB: AHIT) is still getting settled in its new business model, Board of Directors, name change, symbol change, etc., but the company is well-positioned to be a leader in the organic and pharmaceutical-grade CBD oil business. Corix Bioscience, Inc. (OTCQB: AHIT) is an under-the-radar CBD cannabis stock that is positioning to be among the top contenders in the multi-million dollar pharmaceutical-grade industry.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. Full details about which can be found in our full disclosure, which can be found here, http://emerginggrowth.com/722448-2/  Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Add a Comment to this Post

comments